logo
  

AbbVie Seeks Approval For SKYRIZI Based On Data From Three Phase 3 Studies

AbbVie (ABBV) has submitted an application to the FDA seeking approval for risankizumab-rzaa or SKYRIZI, for the treatment of patients 16 years and older with moderate to severe Crohn's disease. The submission is supported by data from three phase 3 studies - ADVANCE, MOTIVATE and FORTIFY.

Crohn's disease is a chronic disease that manifests as inflammation within the gastrointestinal tract, causing persistent diarrhea, abdominal pain, and rectal bleeding.

SKYRIZI is part of a collaboration between Boehringer Ingelheim and AbbVie, with AbbVie leading development and commercialization globally.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Royal Caribbean Group's ultra-luxury brand Silversea Cruises is set to launch the world's first hybrid-powered cruise ship in the summer of 2023. This will also be the first ship with large-scale fuel cell technology to enable emission-free port operations. The fuel cells will provide 100% of power while at port. Affco USA is recalling around 24,461 pounds of frozen raw lamb shoulder products that were not presented for import re-inspection into the U.S., the U.S. Department of Agriculture's Food Safety and Inspection Service or FSIS announced. The recall involves the frozen raw lamb shoulder items that were imported on July 12, 2021. American Express Company (AXP) reported an increase in profit for the third quarter that also topped Wall Street estimates. Consolidated total revenues net of interest expense rose 25 percent year-on-year, primarily reflecting growth in Card Member spending, as well as a rise in the average discount...
Follow RTT